Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Single Dose, Oral, Dose Escalation Phase 1 Study to Evaluate the Safety and Tolerance of MF 101 as Well as the Pharmacokinetics of Its Key Active Components in Healthy Post-Menopausal Women.
NCT00453297 is registered in ClinicalTrials.gov with Bionovo as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Single Dose, Oral, Dose Escalation Phase 1 Study to Evaluate the Safety and Tolerance of MF 101 as Well as the Pharmacokinetics of Its Key Active Components in Healthy Post-Menopausal Women.
- Lead sponsor
- Bionovo
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- October 31, 2006
- Completion date
- April 30, 2007
- Enrollment
- 32 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
healthy